IMMUNOTHERAPY IN MISMATCH REPAIR-DEFICIENT COLORECTAL CANCERS
Grant number: 1120081 | Funding period: 2017 - 2020
A new drug called PD-1 is effective in treating bowel cancers occurring in people at high risk of cancer called Lynch syndrome but little is known why PD-1 is effective at treating these cancer types. Initial studies have found that certain attributes of these cancers such as high amounts of inflammation may help to predict why these cancers respond to PD-1 but further studies of these tumors are needed to identify other tumor characteristics that may help predict responsiveness to PD-1.
Related publications (3)
Receipt of infant HIV DNA PCR test results is associated with a reduction in retention of HIV-exposed infants in integrated HIV care and healthcare services: a quantitative sub-study nested within a cluster randomised trial in rural Malawi
Elasma Milanzi, Victor Mwapasa, Jessica Joseph, Aurelie Jousset, Timothy Tchereni, Andrews Gunda, Jennipher Phiri, Jeanette C Reece
BACKGROUND: Retention of HIV-infected mothers in integrated HIV and healthcare facilities is effective at reducing mother-to-child..
Neoadjuvant Chemoradiotherapy and Tumor Recurrence in Patients with Early T-Stage Cancer of the Lower Rectum
Ian P Hayes, Elasma Milanzi, Peter Gibbs, Jeanette C Reece
BACKGROUND: The role neoadjuvant chemoradiotherapy (nCRT) plays in oncological outcomes in early T-stage rectal cancer is uncertai..